- Home
- PLYA vs NVCR Comparison
PLYA vs NVCR Comparison
Compare PLYA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYA
- NVCR
- Stock Information
- Founded
- PLYA 2006
- NVCR 2000
- Country
- PLYA Netherlands
- NVCR Switzerland
- Employees
- PLYA N/A
- NVCR N/A
- Industry
- PLYA Hotels/Resorts
- NVCR Medical/Dental Instruments
- Sector
- PLYA Consumer Discretionary
- NVCR Health Care
- Exchange
- PLYA Nasdaq
- NVCR Nasdaq
- Market Cap
- PLYA 1.6B
- NVCR 1.9B
- IPO Year
- PLYA N/A
- NVCR 2015
- Fundamental
- Price
- PLYA $13.44
- NVCR $17.38
- Analyst Decision
- PLYA Hold
- NVCR Buy
- Analyst Count
- PLYA 5
- NVCR 6
- Target Price
- PLYA $12.00
- NVCR $32.83
- AVG Volume (30 Days)
- PLYA 2.3M
- NVCR 884.7K
- Earning Date
- PLYA 05-05-2025
- NVCR 04-24-2025
- Dividend Yield
- PLYA N/A
- NVCR N/A
- EPS Growth
- PLYA 8.44
- NVCR N/A
- EPS
- PLYA 0.49
- NVCR N/A
- Revenue
- PLYA $896,462,000.00
- NVCR $621,711,000.00
- Revenue This Year
- PLYA N/A
- NVCR $2.90
- Revenue Next Year
- PLYA $7.68
- NVCR $10.47
- P/E Ratio
- PLYA $27.64
- NVCR N/A
- Revenue Growth
- PLYA N/A
- NVCR 18.27
- 52 Week Low
- PLYA $6.95
- NVCR $14.17
- 52 Week High
- PLYA $13.43
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- PLYA 63.16
- NVCR 48.17
- Support Level
- PLYA $13.42
- NVCR $16.19
- Resistance Level
- PLYA $13.45
- NVCR $17.70
- Average True Range (ATR)
- PLYA 0.02
- NVCR 0.85
- MACD
- PLYA -0.00
- NVCR 0.06
- Stochastic Oscillator
- PLYA 80.00
- NVCR 42.53
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company's segments are Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of HYATT ZIVA, HYATT ZILARA, Hilton, JEWEL RESORTS, and others.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.